×

CLIN LYMPHOMA MYELOMA LEUK 2020 10.1016/j.clml.2019.10.017
Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study
Jung1, KS; Kim, K; Kim, HJ; Kim, SH; Lee, JO; Kim, JS; Lee, JJ; Eom, HS; Min, CK; Shin, HJ

CLIN CANCER RES 2020 10.1158/1078-0432.CCR-19-0694
Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion
Ryu1, D; Kim, SJ; Hong, Y; Jo, A; Kim, N; Kim, HJ; Lee, HO; Kim, K; Park, WY

J AM COLL CARDIOL 2020 10.1016/j.jacc.2019.11.045
Prognostic Value of the Index of Microcirculatory Resistance Over Serum Biomarkers in Cardiac Amyloidosis
Choi1, KH; Lee, JM; Kim, SR; Kim, D; Choi, JO; Kim, SJ; Kim, K; Kim, JS; Koo, BK; Jeon, ES

ANN HEMATOL 2020 10.1007/s00277-019-03904-7
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)
Jo1, JC; Lee, HS; Kim, K; Lee, JJ; Yoon, SS; Bang, SM; Kim, JS; Eom, HS; Yoon, DH; Lee, Y; Shin, HJ; Park, Y; Lee, WS; Do, YR; Mun, YC; Lee, MH; Kim, HJ; Kim, SH; Kim, MK; Lim, SN; Cho, SH; Park, SK; Yi, JH; Lee, JH; Kim, J; Min, CK

LEUKEMIA 2020 10.1038/s41375-020-0711-6
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Bahlis1, NJ; Dimopoulos, MA; White, DJ; Benboubker, L; Cook, G; Leiba, M; Ho, PJ; Kim, K; Takezako, N; Moreau, P; Kaufman, JL; Krevvata, M; Chiu, C; Qin, X; Okonkwo, L; Trivedi, S; Ukropec, J; Qi, M; San-Miguel, J

AM J HEMATOL 2020 10.1002/ajh.25726
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)
Lee1, HS; Kim, K; Kim, SJ; Lee, JJ; Kim, I; Kim, JS; Eom, HS; Yoon, DH; Suh, C; Shin, HJ; Mun, YC; Kim, MK; Lim, SN; Choi, CW; Kang, HJ; Yoon, SS; Min, CK

ANN LAB MED 2020 10.3343/alm.2020.40.1.88
Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults
Choi1, S; Kim, YJ; Yoo, KH; Sung, KW; Koo, HH; Kim, SJ; Jang, JH; Kim, K; Jung, CW; Huh, HJ; Kang, ES

MEDICINE 2020 10.1097/MD.0000000000018905
Tc-99m-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis Potential clinical implications
Lee1, JH; Kim, K; Choi, JO; Kim, SJ; Jeon, ES; Choi, JY

LEUKEMIA 2020 10.1038/s41375-019-0539-0
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Facon1, T; Dimopoulos, MA; Meuleman, N; Belch, A; Mohty, M; Chen, WM; Kim, K; Zamagni, E; Rodriguez-Otero, P; Renwick, W; Rose, C; Tempescul, A; Boyle, E; Manier, S; Attal, M; Moreau, P; Macro, M; Leleu, X; Chretien, ML; Ludwig, H; Guo, S; Sturniolo, M; Tinel, A; Monzini, MS; Costa, B; Houck, V; Hulin, C; Mary, JY

BONE MARROW TRANSPL 2019 10.1038/s41409-019-0629-7
Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
Lee1, YJ; Moon, JH; Sohn, SK; Kim, SJ; Jung, SH; Lee, JJ; Jo, JC; Shin, HJ; Lee, WS; Lee, JH; Bae, SH; Kim, MK; Lee, HS; Kim, K; Min, CK

IMMUNOL LETT 2019 10.1016/j.imlet.2019.10.005
A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model
Hong1, SH; Kim, K; Shin, JS; Chung, H; Park, CG

Blood Cancer J 2019 10.1038/s41408-019-0245-1
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network
Soekojo1, CY; Kim, K; Huang, SY; Chim, CS; Takezako, N; Asaoku, H; Kimura, H; Kosugi, H; Sakamoto, J; Gopalakrishnan, SK; Nagarajan, C; Wei, Y; Moorakonda, R; Lee, SL; Lee, JJ; Yoon, SS; Kim, JS; Min, CK; Lee, JH; Durie, B; Chng, WJ

J CLIN APHERESIS 2019 10.1002/jca.21734
Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma
Park1, Y; Kim, DS; Jeon, MJ; Lee, BH; Yu, ES; Kang, KW; Lee, SR; Sung, HJ; Nam, MH; Yoon, SY; Choi, CW; Kang, ES; Cho, D; Kim, K; Kim, BS; Kim, DW; Kim, SJ

EUR J CANCER CARE 2019 10.1111/ecc.13089
Influence of time lapse after cancer diagnosis on the association between unmet needs and quality of life in family caregivers of Korean cancer patients
Shin1, J; Ko, H; Lee, JW; Kim, K; Song, YM

SCI REP-UK 2019 10.1038/s41598-019-48513-6
Prognostic values of novel biomarkers in patients with AL amyloidosis
Kim1, D; Lee, G; Choi, JO; Kim, K; Kim, S; Ju, ES; Jeon, ES
외 다수